Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects

Eugenia Papalexi1*, Andreas Galanopoulos1, Dimitrios Kontis2, Maria Markopoulou3, Georgia Balta4, Evaggelos Karavelas5, Panagiotis Panagiotidis6, Themistoklis Vlachos7 and Anders Ettrup8

Abstract

Background: Functional recovery is an important treatment goal in major depressive disorder (MDD). This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose–response was also assessed.

Methods: This was a non-interventional, prospective, multicenter study conducted in Greece. Adult outpatients with MDD (n=336) initiating vortioxetine (5–20 mg/day flexible dosing) as treatment for a current major depressive episode were followed for 3 months. Analyses were stratified according to vortioxetine dosage at 3 months: 5–10 mg/day versus 15–20 mg/day. Functioning was assessed using the Sheehan Disability Scale (SDS).

Results: Mean ± standard error SDS total score decreased (improved) from 18.7 ± 0.3 at baseline to 12.9 ± 0.3 after 1 month of vortioxetine treatment and 7.8 ± 0.3 after 3 months (p < 0.001 vs. baseline for all comparisons). Functional recovery (SDS score ≤ 6) was achieved in 14.6% of patients after 1 month of treatment and 48.4% of patients after 3 months. Improvement from baseline in SDS total and domain scores at 3 months was more pronounced in patients receiving vortioxetine 15–20 mg/day than in those receiving vortioxetine 5–10 mg/day. The mean ± standard error change in SDS total score from baseline was 9.2 ± 0.8 in the 5–10 mg/day group and 12.1 ± 0.4 in the 15–20 mg/day group (p < 0.001). Limitations of this study include its non-interventional study design and lack of a control group or active comparator.

Conclusions: Statistically significant and clinically relevant improvements in functioning were seen in patients with MDD treated with vortioxetine in a real-world setting. Higher doses of vortioxetine were associated with significantly greater improvements in functioning.

Keywords: Major depressive disorder (MDD), Functioning, Vortioxetine, Real-world effectiveness, Dose-response

Introduction

Major depressive disorder (MDD) is a common and debilitating condition estimated to affect more than 160 million people worldwide [1]. MDD is a multidimensional disease characterized by emotional, cognitive, and somatic symptoms that significantly compromise functioning [2]. Functional recovery is the current treatment goal for patients with MDD [3–6]; however, functional impairment may persist even after resolution of other symptoms [7]. Residual functional impairment following remission of mood symptoms in patients with MDD has been shown to be a predictor of subsequent relapse [8].

Vortioxetine is a multimodal antidepressant with a unique mechanism of action [9]. It acts both as an
inhibitor of the serotonin transporter and as a modulator of several serotonin receptor subtypes, thereby directly and indirectly influencing neurotransmitter systems relevant to the neurobiology of depression, including serotonin, noradrenaline, dopamine, acetylcholine, histamine, glutamate, and gamma-aminobutyric acid systems [9–11]. First approved by the US Food and Drug Administration for the treatment of adults with MDD in 2013, vortioxetine has since been licensed in more than 80 countries worldwide. Vortioxetine has an approved therapeutic dose range of 5–20 mg/day [12, 13]. In most countries, the recommended starting dose of vortioxetine in adult patients with MDD is 10 mg once daily. Depending on individual patient response, the dosage of vortioxetine may be increased to a maximum of 20 mg/day or decreased to a minimum of 5 mg/day.

Early optimized antidepressant dosing is likely to afford the best possible treatment outcomes [3, 5]. Indeed, subtherapeutic dosing has been shown to contribute to early withdrawal from antidepressant treatment in patients with MDD [14]. A recent analysis of more than 50,000 patients who were prescribed selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression found that 60% never received the treatment dose reported to exert maximum antidepressant effect [15]. However, finding the right dose for each patient can be challenging in routine practice. A dose–response relationship for antidepressant efficacy remains controversial [16–19], and individual patients may respond differently to the same drug dosage. Nevertheless, it would be helpful to provide clinicians with meaningful guidance on how to optimize antidepressant dosage so that patients receive maximum benefit from their treatment.

Vortioxetine is one of the few antidepressants with a dose–response relationship demonstrated in fixed-dose, randomized controlled clinical trials [20, 21]. The present study was undertaken to assess the real-world effectiveness of vortioxetine for the treatment of patients with MDD in Greece, with particular focus on the effect of treatment on patients’ functioning. The impact of vortioxetine dosage on treatment response was also assessed.

Methods
Study design
This was a 3-month, non-interventional, prospective, multicenter study conducted in private psychiatric offices or in public hospitals in Greece. Participants were adult (aged ≥ 18 years) outpatients with MDD who were initiating vortioxetine as first- or second-line treatment for a current major depressive episode at their physician’s discretion. Vortioxetine was administered at a flexible dosage of 5–20 mg/day according to local prescribing information [13]. In Greece, the starting and recommended dosage of vortioxetine in adults aged < 65 years is 10 mg/day. According to the prescribing information, vortioxetine may be increased to a maximum of 20 mg or decreased to a minimum of 5 mg once daily “depending on individual patient response” [13]. Consequently, healthcare providers were free to adjust the vortioxetine dosage for each patient based on their own clinical practice and the patient’s individual needs. Vortioxetine treatment was not free for the study participants; patients were required to meet the usual prescription charges for their medication. Patients with schizophrenia or any other psychotic disorder, bipolar disorder, substance-use disorders, dementia or other neurodegenerative diseases significantly impacting cognitive functioning, or mood disorders due to an underlying general medical condition were excluded from study participation. Patients considered at significant risk of suicide or who had attempted suicide within the last 6 months were also excluded.

Study assessments were conducted at baseline and after 1 and 3 months of vortioxetine treatment. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All experimental protocols were approved by the institutional review boards at the two coordinating hospitals (Psychiatric Hospital of Attica and Psychiatric Hospital of Thessaloniki). At the time the study was conducted, ethical approval for observational studies was not required at a national level. All patients provided written informed consent for participation.

Study objectives
The primary objective of this study was to assess the real-world effectiveness of vortioxetine on patient functioning (measured using the Sheehan Disability Scale [SDS]) and the rate of functional recovery for the total treatment duration, as well as the impact of baseline patient and MDD characteristics on the change in patient functioning (difference in SDS total score) after 3 months of vortioxetine treatment. Secondary objectives included assessment of the effectiveness of vortioxetine on depression severity (assessed by the Montgomery–Åsberg Depression Rating Scale [MADRS] and the 9-item Patient Health Questionnaire [PHQ-9]), cognitive symptoms (assessed using the 20-item Perceived Deficits Questionnaire–Depression [PDQ-D-20]), and patients’ general clinical condition (assessed using the Clinical Global Impression–Severity [CGI-S] scale) for the total treatment duration, i.e. at baseline and 1 and 3 months post baseline. The effect of vortioxetine dosage on patient functioning (SDS change/difference) and severity of mood symptoms (MADRS change/difference) after 3 months of treatment was also assessed. Safety assessment was not a primary
Objective of this study; however, adverse events leading to withdrawal from treatment were recorded.

**Patient-reported outcomes**

Patients assessed their functioning using the SDS [22, 23]. This brief self-report measure assesses functional impairment over the previous 7 days across three domains: work/school, social life/leisure, and family/home life. The level of impairment for each domain is rated using a visual analog scale ranging from 0 (not at all) to 10 (very severe). Scores from the individual domains are combined to generate the SDS total score, ranging from 0 (unimpaired) to 30 (highly impaired). In this study, all patients completed all sections of the SDS. Functional recovery was defined as an SDS total score ≤ 6 [23, 24].

Patients also rated the severity of their depressive symptoms using the PHQ-9 [25] and the severity of cognitive symptoms using the PDQ-D-20 [26, 27].

**Clinician-rated outcomes**

Clinicians evaluated depression severity using the MADRS [28] and the CGI-S [29, 30]. The MADRS anhedonia factor score was also calculated (i.e. the sum of MADRS items 1, 2, 6, 7, and 8) [31, 32]. MADRS total score cut-offs for mild, moderate, and severe depression were <20, 20–34, and ≥ 35 points, respectively [33]. Response was defined as ≥ 50% improvement in MADRS total score from baseline; remission was defined as MADRS total score ≤ 12 points.

**Statistical methods**

Sample size estimation was based on calculation of the estimated 95% confidence interval (CI; normal approximation) for the change in SDS score (primary study outcome) after 3 months of vortioxetine treatment. In the open-label AtWoRC study [34], the mean ± standard deviation (SD) change (improvement) in SDS total score after 3 months of vortioxetine treatment was approximately 10.0 ± 9.0 points. The accuracy of the corresponding 95% CI was assumed to be 10% of the above-mentioned SD, which is 0.9 (i.e. almost 1 point on the SDS scale), giving a required sample size of 385 patients. In the present study, the corresponding SD of mean change in SDS total score was 0.7; thus, the study provided higher precision than that required based on the sample size calculation.

All enrolled patients who met the study inclusion criteria were included in this analysis. All analyses were conducted on observed cases (i.e. patients with missing data for particular variables were excluded from the corresponding analyses). For the dose–response analysis, patients were stratified into two groups according to their vortioxetine dosage at the end of the 3-month study period (5–10 mg/day vs. 15–20 mg/day).

Categorical variables are presented as number (%), while continuous variables are reported as means and SD or standard error (SE). For all study outcomes (SDS, MADRS, PHQ-9, PDQ-D-20, and CGI-S), the effectiveness of vortioxetine over the total treatment duration was assessed using repeated measures analysis of variance with Greenhouse–Geisser correction [35]. For each of these variables, if the corresponding p-value was < 0.05, a paired t test was used to assess the pairwise differences between visits (Bonferroni correction). Cochran’s Q test was used to assess the change in the percentage of patients achieving functional recovery (i.e. SDS score ≤ 6) over time. If the corresponding p-value was < 0.05, McNemar’s test was used to assess the three pairwise comparisons between visits (Bonferroni correction).

The impact of baseline characteristics on the real-world effectiveness of vortioxetine on patient functioning (measured by SDS) was assessed using multiple linear regression (stepwise selection), with patient demographic characteristics, MDD history, MDD management, MDD severity (baseline MADRS total score), and baseline SDS total score as independent variables, and the difference in SDS score between the third minus the first (baseline) visit as the dependent variable. The effect of vortioxetine dosage on the change in SDS and MADRS scores after 3 months of treatment was also assessed using multiple linear regression (stepwise selection), with difference in score between the third minus the first (baseline) visit as the dependent variable. The corresponding baseline score (SDS or MADRS), vortioxetine dosage, and patient/MDD characteristics were used as explanatory variables.

All statistical analyses were performed using R version 3.6.3 [36]. For all statistical tests, the significance level was set at 0.05. All p-values should be considered nominal.

**Results**

**Study population**

Between January 15 and September 18, 2019, 337 patients were enrolled into the study, 336 of whom were included in this analysis; one patient was excluded due to missing baseline data. Baseline demographics and clinical characteristics are shown in Table 1. The mean ± SD age of study participants was 47.9 ± 14.3 years, and almost two-thirds (64.3%) were female. Over half of all patients had received higher education (53.3%) and 56.0% were in full- or part-time employment. This was the first depressive episode for approximately half of all patients (48.5%). Mean ± SD duration of MDD was 3.5 ± 6.1 years.

Vortioxetine dosage at each visit is shown in Table 2. At baseline, most patients were receiving vortioxetine
Of the 311 patients who completed the 3-month visit, 200 (64.3%) were receiving vortioxetine 15–20 mg/day. Twenty-six patients (7.7%) discontinued treatment with vortioxetine (nine by the second study visit at 1 month and the remaining 17 by the final study visit at 3 months). The most common reasons for treatment discontinuation were lost to follow-up (n = 10), lack of efficacy (n = 5), and adverse events (n = 4; nausea/vomiting in all cases).

### Table 1 Baseline demographics and clinical characteristics (observed cases)

| Characteristic                        | Total (n = 336) |
|---------------------------------------|-----------------|
| Age, years                            | 47.9 ± 14.3     |
| Sex, n (%)                            |                 |
| Female                                | 216 (64.3)      |
| Male                                  | 120 (35.7)      |
| Educational level, n (%)              |                 |
| Primary education                     | 24 (7.1)        |
| Secondary education                   | 133 (39.6)      |
| Higher education                      | 179 (53.3)      |
| Working status, n (%)                 |                 |
| Working full-time                     | 139 (41.4)      |
| Working part-time                     | 49 (14.6)       |
| Unable to work due to depression/acute depression | 12 (3.6) |
| Unable to work due to reasons other than depression | 8 (2.4) |
| Seeking work                          | 17 (5.1)        |
| Not working by choice                 | 111 (33.0)      |
| Living status, n (%)                  |                 |
| Living with a partner                 | 274 (81.5)      |
| Living alone                          | 62 (18.5)       |
| Newly diagnosed, n (%)                | 182 (54.2)      |
| Family history of MDD, n (%)          | 108 (32.1)      |
| MDD duration, years                  | 3.5 ± 6.1       |
| No. of depressive episodes, n (%)     |                 |
| 1                                     | 163 (48.5)      |
| 2                                     | 100 (29.8)      |
| ≥ 2                                   | 73 (21.7)       |

**MDD** major depressive disorder

Values are mean ± standard deviation unless otherwise indicated

### Table 2 Vortioxetine dosage at each study visit (observed cases)

| Vortioxetine dosage | Patients (%) |
|---------------------|--------------|
|                     | Baseline (n = 317)* | Month 1 (n = 329) | Month 3 (n = 311) |
| 5–10 mg/day         | 89.6          | 58.7              | 35.7              |
| 15–20 mg/day        | 10.4          | 41.3              | 64.3              |

*Vortioxetine dose data not available for all patients at baseline

5–10 mg/day (89.6%). Of the 311 patients who completed the 3-month visit, 200 (64.3%) were receiving vortioxetine 15–20 mg/day. Twenty-six patients (7.7%) discontinued treatment with vortioxetine (nine by the second study visit at 1 month and the remaining 17 by the final study visit at 3 months). The most common reasons for treatment discontinuation were lost to follow-up (n = 10), lack of efficacy (n = 5), and adverse events (n = 4; nausea/vomiting in all cases).

### Effect on patient functioning

As shown in Fig. 1, mean ± SE SDS total score decreased (i.e. improved) significantly from 18.7 ± 0.3 at baseline to 12.9 ± 0.3 after 1 month of vortioxetine treatment and 7.8 ± 0.4 after 3 months (Greenhouse–Geisser corrected: F = 557, degrees of freedom [df] = 1.6, p < 0.001; t test, p < 0.001 for all pairwise comparisons between visits). The mean ± SE reduction in SDS total score at the third visit compared with the baseline visit was 11.0 ± 0.4 points (corresponding 95% CI: 10.3, 11.8); this represents a 58% reduction from baseline. Significant improvement was observed in all three SDS domains over the 3 months of vortioxetine treatment (work/school: F = 343, df = 1.6, p < 0.001; social life: F = 504, df = 1.7, p < 0.001; home/family life: F = 447, df = 1.7, p < 0.001; t test, p < 0.001 for all pairwise comparisons). Functional recovery (SDS score ≤ 6) was achieved in 14.6% of patients after 1 month of vortioxetine treatment and 48.4% of patients after 3 months (Cochran’s Q = 222, df = 2.0, p < 0.001; McNemar’s test, p < 0.001 for all pairwise comparisons).

SDS total score was the only baseline characteristic found to be significantly related to improvement in functioning by multiple linear regression analysis; greater improvement was seen in patients with higher baseline SDS total score (multiple linear regression coefficient B = 0.6, t statistic = 9.2, p < 0.001).
Effect on mood and cognitive symptoms

Significant improvements were observed across all depression-related outcomes over the study period. Mean ± SE MADRS total score decreased from $32.7 \pm 0.5$ at baseline to $20.1 \pm 0.6$ after 1 month of vortioxetine treatment and $9.7 \pm 0.5$ after 3 months (Greenhouse–Geisser correction $F = 1318$, df = 1.7, $p < 0.001$; $t$ test, $p < 0.001$ for all pairwise comparisons between visits); a decrease of $23.4 \pm 0.5$ points at the third visit compared with the baseline visit (Fig. 2A). The mean ± SE MADRS anhedonia factor score decreased from $18.9 \pm 0.3$ at baseline to $12.1 \pm 0.3$ after 1 month of vortioxetine treatment and $5.9 \pm 0.3$ after 3 months ($F = 16,469$, df = 1.7, $p < 0.001$; $t$ test, $p < 0.001$ for all pairwise comparisons), a decrease of $13.2 \pm 0.3$ points at the third visit compared with the baseline visit.
This corresponds to a 72% reduction from baseline in MADRS total score and a 70% reduction in MADRS anhedonia factor score over the 3 months of vortioxetine treatment. Improvements were observed across all individual MADRS items, suggesting that vortioxetine had broad efficacy across the spectrum of depressive symptoms (Fig. 3).

After 1 month of vortioxetine treatment, 34.2% of patients were classed as MADRS responders (i.e. had experienced ≥ 50% improvement in MADRS total score) and 25.2% achieved symptomatic remission (i.e. achieved MADRS total score ≤ 12 points). Corresponding rates of response and remission after 3 months of vortioxetine treatment were 84.3% and 67.6%, respectively.

The mean ± SE CGI-S score improved from 4.7 ± 0.1 (markedly ill) at baseline to 3.5 ± 0.1 (moderately–mildly ill) at 1 month and 2.2 ± 0.1 (borderline ill) at 3 months (Greenhouse–Geisser correction $F=922$, df = 1.7, $p < 0.001$; t test, $p < 0.001$ for all pairwise comparisons between visits). The proportion of patients classed as not at all ill or borderline ill according to CGI-S score was 18.5% after 1 month of vortioxetine treatment and 64.6% after 3 months.

Over the 3 months of vortioxetine treatment, patients reported a 71% reduction from baseline in the severity of depressive symptoms assessed by the PHQ-9 (Fig. 2C) and a 68% reduction in perceived cognitive symptoms assessed by the PDQ-D-20 (Fig. 2D).

Effect of vortioxetine dosage

Baseline patient characteristics according to vortioxetine dosage at 3 months are shown in Supplementary Table 1 (see Additional file 1). Improvement in SDS total score from baseline was more pronounced in patients receiving vortioxetine 15–20 mg/day at 3 months than in those receiving vortioxetine 5–10 mg/day, and this dose–response relationship was apparent across all SDS domains (Fig. 4). The improvement in mean ± SE SDS total score was 9.2 ± 0.8 in the 5–10 mg/day group and 12.1 ± 0.4 in the 15–20 mg/day group (multiple linear regression, $B=0.6$, t statistic = 9.1, $p < 0.001$). Significantly greater improvements were seen in patients receiving vortioxetine 15–20 mg/day versus 5–10 mg/day for all SDS domains. The improvement in the work/school domain score was 2.6 ± 0.3 in the 5–10 mg/day group versus 3.7 ± 0.2 in the 15–20 mg/day group ($B=0.8$, t statistic = 3.1, $p = 0.002$). Respective improvements were 3.3 ± 0.3 versus 4.3 ± 0.2 for the social life domain score ($B=0.7$, t statistic = 2.8, $p = 0.005$), and 3.3 ± 0.3 versus 4.1 ± 0.2 for the family/home life domain score ($B=0.7$, t statistic = 2.6, $p = 0.009$). After 3 months of vortioxetine treatment, the percentage reduction in SDS total score from baseline was 63% in patients receiving vortioxetine 15–20 mg/day compared with 51% in those who were receiving vortioxetine 5–10 mg/day. After 3 months of vortioxetine treatment, functional recovery (SDS score ≤ 6) was achieved in 50.0% of patients receiving vortioxetine 15–20 mg/day and 45.9% of those receiving vortioxetine 5–10 mg/day.
The improvement in mean ± SE MADRS total score from baseline over the 3 months of vortioxetine treatment was numerically greater in patients receiving vortioxetine 15–20 mg/day than in those receiving vortioxetine 5–10 mg/day (24.5 ± 0.7 vs. 21.5 ± 0.8 points, respectively); however, this difference was not found to be significant using multiple linear regression stepwise analysis. The only parameter that entered the model was MADRS baseline score: patients with more severe MDD at baseline showed greater MADRS improvement. However, physicians prescribed the higher dosage to patients with higher MADRS scores at baseline (mean ± SE MADRS total score at baseline, 34.8 ± 0.8 in patients receiving 15–20 mg/day vs. 29.8 ± 0.9 in those receiving 5–10 mg; t test statistic = -4.6, df = 309, p-value < 0.001).

**Discussion**

Broad improvements in symptoms of depression were seen in patients with MDD treated with vortioxetine in real-world settings in this study, with statistically significant and clinically relevant improvements observed in patient-reported functioning assessed using the SDS. Patients reported similar improvements across all three domains of the SDS (work/school, social life/leisure, and family/home life). Functional recovery (defined as an SDS score ≤ 6) was achieved in approximately 15% of patients after 1 month of vortioxetine treatment and approximately 50% of patients after 3 months. Functional recovery is increasingly recognized to be an important treatment goal in patients with MDD [3–6]. Symptomatic response (defined as ≥ 50% improvement in MADRS total score from baseline) was achieved by almost 85% of patients after 3 months of vortioxetine treatment, with just over two-thirds of all patients achieving remission from depressive symptoms by the end of follow-up (i.e., MADRS total score ≤ 12 points). Our findings are in line with results of a meta-analysis of data from nine short-term, randomized controlled studies showing improved overall functioning and high rates of functional remission in adults with MDD treated with vortioxetine 5–20 mg/day [37].

Broad therapeutic efficacy of vortioxetine in patients with MDD has been demonstrated in other recently completed real-world studies [34, 38–40]. In another recent 24-week, observational, prospective cohort study of similar design in outpatients with MDD initiating treatment with vortioxetine in routine care settings in Canada, France, Italy and the USA (the RELIEVE study), clinically relevant improvements in overall functioning, depressive symptoms, cognitive symptoms and performance, and health-related quality of life were reported over the 6-month treatment period [40]. Of note, greater improvement in functioning as assessed by mean change in SDS total score was seen after 3 months of vortioxetine treatment in the present study than in the multinational RELIEVE study (-11 versus -7 points, respectively) [40]. This may be due to differences in patient population, treatment line, or vortioxetine dosage. For example, in the present study, almost half of all patients were experiencing their first depressive episode compared with only 20% of those in the RELIEVE study. In RELIEVE, the greatest clinical benefits were achieved when vortioxetine was used as a first-line treatment [40].

The observed improvements in self-reported cognitive symptoms during treatment with vortioxetine in the present study are consistent with results of previous studies [34, 38, 41–46]. It seems reasonable to assume that the positive impact of vortioxetine on functioning in patients with MDD is at least in part due to the beneficial effect of treatment on cognitive symptoms. In a study in patients with MDD who were either initiating or undergoing their first switch of antidepressant monotherapy, patient-reported cognitive symptoms (assessed using the shorter 5-item Perceived Deficits Questionnaire) were found to be independently associated with patient functioning throughout the 2 years of follow-up [47, 48].

In the present study, few patients (1.2%) discontinued treatment due to adverse events (nausea/vomiting in all
undertaken; with increased experience and evidence, in routine clinical practice at the time these studies were undertaken; with increased experience and evidence, clinicians may be more likely to increase patients’ vortioxetine dosage for early optimization of clinical response.

Interpretation of these findings should take into account the inherent limitations of the naturalistic and observational study design, and the lack of control group or active comparator. In addition, we cannot rule out potential for bias caused by clinicians overestimating the effects of vortioxetine on patients’ depressive symptoms when administering the MADRS and CGI-S. However, it should be noted that the positive effects of vortioxetine on depressive symptoms were confirmed by patients using self-reported questionnaires (PHQ-9 and PDQ-D-20), supported by the observed improvement in patient functioning (assessed using the SDS).

As such, the consistent effects of vortioxetine across the spectrum of depressive symptoms and functioning measures were unlikely to have occurred by chance. A further possible limitation is that patients with MDD generally require long-term treatment and patients in this study were followed for only 3 months. However, in another observational study in outpatients with MDD receiving treatment with vortioxetine in routine care settings in Canada, France, Italy and the USA, the significant improvements observed in overall functioning, depressive symptoms, cognitive symptoms and performance, and health-related quality of life that were achieved within 12 weeks of treatment initiation (i.e., at the first post-baseline assessment time point) were sustained over a period of 6 months [40]. In addition, we did not assess cognition using objective neurocognitive tests. However, the improvement in cognitive symptoms reported by patients using the PDQ-D-20 was indirectly confirmed by the observed improvement in the clinician-administered MADRS item that measures concentration difficulties. Finally, the analysis of the effects of vortioxetine dosage was based on pooled dosages (5–10 and 15–20 mg/day) rather than individual doses (5, 10, 15, or 20 mg/day). Important strengths of this study include the real-world setting, the broad inclusion criteria, the relatively large patient population, and the use of both patient-reported and clinician-rated outcome measures to assess symptom severity and functioning.

In summary, in this study, statistically significant and clinically relevant improvements in patient-reported functioning were seen in patients with MDD treated with vortioxetine in a real-world setting. Higher dosages of vortioxetine were associated with significantly greater improvements in functioning and higher rates of functional recovery. Our findings suggest that vortioxetine dosage can be increased to 20 mg/day early in the course of treatment in patients with MDD in order to achieve optimal therapeutic benefit and promote functional recovery. The observed dose–response relationship allows prescribers to increase vortioxetine dosage to optimize clinical response in patients with MDD as a possible alternative to switching to another antidepressant medication.

Abbreviations
CGI-S: Clinical Global Impression–Severity; CI: confidence interval; df: degrees of freedom; MADRS: Montgomery–Åsberg Depression Rating Scale; MDD: major depressive disorder; PDQ-D-20: 20-item Perceived Deficits Questionnaire–Depression; PHQ-9: 9-item Patient Health Questionnaire; SD: standard deviation; SDS: Sheehan Disability Scale; SE: standard error; SSRI: selective serotonin reuptake inhibitor.
Acknowledgements
The authors would like to thank the following principal investigators at the participating study sites:
Chrysoula Anagnostara, Dimitrios Belimbasakis, Ioannis Bougiouklis, Petros Dounas, Dimitrios Goulas, Panagiota Kakakavas, Eleni Kologerou, Dimitris Karaiskos, Dimitris Karakoutsas, Konstantinos Kyziridis, Stamata Mageira, Maria Maroula, Ioannafylla Mylonaki, Christoforos Nestoris, Kalliopi Nikolacou, Dimitrios Pappas, Dimitrios Partsaftylidis, Angeliki Petropoulos, Panagiota Rossis, Dimitris Roukias, Matthoas Sandis, Nikolaos Sidinopoulo, Eleni Tsiolka, and Dimitris Vassos. Statistical analyses were performed by BIO-STATISTICS, funded by Lundbeck Hellas. Editorial assistance was provided by Jennifer Coward for Piper Medical Communications, funded by H. Lundbeck A/S.

Authors’ contributions
All authors – E.P., A.G., D.K., M.M., G.B., E.K., P.P., and A.E. – materially participated in the research, and contributed to the interpretation of the results of the analyses and the preparation of this article and approved the final article.

Competing interests
Janssen Cilag. G.B., E.K., P.P., and T.V. report no other competing interests. Pharmaceuticals, and honoraria as a speaker from Lundbeck Hellas and conferences from Lundbeck Hellas, Janssen Cilag, Pfizer, Innovis, and Anabiosis support for participation in conferences from Lilly and Janssen and honoraria (to their respective institutions) from Lundbeck Hellas. D.K. has also received support for participation in conferences from Lilly and Janssen and honoraria as a speaker from Lundbeck Hellas and Janssen Cilag. G.B., E.K., PP, and TV report no other competing interests.

Consent for publication
Not applicable.

Consent for publication
Not applicable.

Additional file 1.

Additional file 1.

Availability data and materials
The authors confirm that the data supporting the findings of this study are included in this article and its additional supplementary information files. The authors may be contacted for further data sharing.

Declarations

Ethics approval and consent to participate
The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All experimental protocols were approved by the institutional review boards at the two coordinating hospitals (Psychiatric Hospital of Attica and Psychiatric Hospital of Thessaloniki). At the time the study was conducted, ethical approval for observational studies was not required at a national level. All patients provided written informed consent for participation.

Consent for publication
Not applicable.

Competing interests
E.P. and A.G. are employees of Lundbeck Hellas. A.E. is an employee of H. Lundbeck A/S. D.K., M.M., G.B., E.K., PP, and T.V. received research funding (to their respective institutions) from Lundbeck Hellas. D.K. has also received support for participation in conferences from Lilly and Janssen and honoraria as a speaker from Janssen. M.M. has also received support for participation in conferences from Lundbeck Hellas, Janssen Cilag, Pfizer, Innovis, and Anabiosis Pharmaceuticals, and honoraria as a speaker from Lundbeck Hellas and Janssen Cilag. G.B., E.K., PP, and T.V. report no other competing interests.

Author details
1 Lundbeck Hellas, 109 Kifissias Avenue & Sina, 11524 Marousi, Athens, Greece.
2 4th Psychiatric Department, Psychiatric Hospital of Attica, Athens, Greece.
3 Department of Forensic Psychiatry, Psychiatric Hospital of Thessaloniki, Stavropoulis, Thessaloniki, Greece.
4 Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
5 Ensynais-thisis, Thessaloniki, Greece.
6 Department of Psychiatry, 424 General Military Hospital of Thessaloniki, Thessaloniki, Greece.
7 Department of Psychiatry, 251 Airforce Military Hospital, Athens, Greece.
8 H. Lundbeck A/S, Valby, Denmark.

References
1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Washington, DC: American Psychiatric Association, 2013.
3. Habert J, Katzman MA, Oluboka OJ, McIntyre RS, McIntosh D, MacQueen GM, Khullar A, Milev RV, Kjemnsted KD, Chotka PR, Kennedy SH. Functional recovery in major depressive disorder: focus on early optimized treatment. Prim Care Companion CNS Disord. 2016;18. https://doi.org/10.4088/PCC.1501926.
4. Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, Sareen J, Song W-Y, Kennedy SH, MacQueen GM, Milev RV, Parikh SV, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry. 2016;61:510–523.
5. Oluboka OJ, Katzman MA, Habert J, McIntosh D, MacQueen GM, Milev RV, McIntyre RS, Blier P. Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient. Int J Neuropsychopharmacol. 2018;21:128–144.
6. Sheehan DH, Nakagome K, Asami Y, Sippadopulos EA, Boucher M. Restoring function in major depressive disorder: A systematic review. J Affect Disord. 2017;215:299–313.
7. Ish-Hak WW, James DM, Mirocha J, Yousef H, Tobia G, P S, Collison KL, Cohen RM. Patient-reported functioning in major depressive disorder. Ther Adv Chronic Dis. 2016;7:160–169.
8. Ish-Hak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord. 2013;151:59–65.
9. Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov. 2019;14:81–89.
10. Chen G, Hajej AM, Areberg J, Nomikos G. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57:673–686.
11. Sanchez C, Asin KE, Artiga F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.
12. Food and Drug Administration. Trintellix (vortioxetine): highlights of prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204447s017lbl.pdf. Accessed 11 Nov 2021.
13. European Medicines Agency. Brintellix (vortioxetine): summary of product characteristics. 2020. https://www.ema.europa.eu/en/docu ments/product-information/brintellix-epar-product-information_en.pdf. Accessed 11 Nov 2021.
14. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25:2289–2304.
15. Lisinska A, Hieronymus F, Eriksson E, Wallerstedt SM. Low SSRI dosing in clinical practice—a register-based longitudinal study. Acta Psychiatr Scand. 2021;143:434–443.
16. Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogues Clin Neurosci. 2005;7:249–262.
17. Hieronymus F, Nilsson S, Eriksson E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry. 2016;6:e834.
18. Jakubovski E, Vangondal AL, Freemantle N, Taylor MJ, Bloch MH. Systematic review and meta-analysis. Dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry. 2016;173:174–183.

Received: 16 November 2021   Accepted: 29 June 2022
Published online: 12 August 2022
19. Braun C, Adams A, Rink L, Bisch T, Kruh K, Baethge C. In search of a dose-response relationship in SSRI—a systematic review, meta-analysis, and network meta-analysis. Acta Psychiatr Scand. 2020;142:430–442.

20. Thase ME, Mahabreshwarkar AR, Drigheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26:979–993.

21. Iovieno N, Papakostas GI, Feeny A, et al. Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset. J Clin Psychiatry. 2021;82:20:13682.

22. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11 Suppl 3:89–95.

23. Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23:70–83.

24. Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2011;26:75–83.

25. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613.

26. Fehnel, SE, Forsyth, BH, Dibenedetti DB, Danchenko N, François C, Brevig, RM. A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord. 2018;227:803–809.

27. Haro JM, Hammer-Helmich L, Jaroszewicz B, Feeny A, et al. Vorticetin on cognitive function in patients with major depressive disorder. J Psychopharmacol. 2018;14:239–249.

28. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.

29. Coin G, Van Der Laarse A, Van Der Meer J, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17.

30. Snath RP, Hamro PM, Newby PA, Teale C. Grade scores of the Montgomery-Åsberg depression and the clinical anxiety scales. Br J Psychiatry. 1986;148:599–601.

31. Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in work productivity and the relationship with cognitive symptoms (AtWoRC): Primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2019;24:338–347.

32. Greenhouse SW, Geiser S. On methods in the analysis of profile data. Psychometrika. 1959;24:95–112.

33. R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria. 2016. http://www.R-project.org/. Accessed 11 Nov 2021.

34. McIntyre RS, Floroa I, Tonnor B, Loft H, Lam RW, Christensen MC. Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry. 2017;78:115–121.

35. Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder. A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord. 2018;227:803–809.

36. Phan L, McIntyre RS. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder: the 2-year PERFORM study. Neuropsychiatr Dis Treat. 2018;14:239–249.

37. Lam RW, Lamy FX, Danchenko N, Yarlas A, White AK, Ribe V, Saragossi D. Psychometric validation of the Perceived Deficits Questionnaire—Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder. Neuropsychiatr Dis Treat. 2018;14:2861–2877.

38. Fagiolini A, Florea I, Katzen MR, Katzman MA, Pulosan M, Simonson K, Hammer-Helmich L. Efficacy of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the RELIEVE study. Front Psychiatry. 2022;13:824831.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: https://biomedcentral.com/submissions